Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1711 to 1725 of 2009 results for nice guidelines

  1. Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)

    This evidence summary has been updated and replaced by NICE guideline 115.

  2. Parkinson's disease with motor fluctuations: safinamide (ES6)

    This evidence summary has been updated and replaced by NICE guideline NG71.

  3. Partial-onset seizures in epilepsy: zonisamide as monotherapy (ESNM17)

    This evidence summary has been updated and replaced by NICE guideline NG217.

  4. Impedance-controlled endometrial ablation for menorrhagia (IPG104)

    Summary --> This guidance has been updated and replaced by NICE guideline CG44.

  5. Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

    This evidence summary has been updated and replaced by NICE guideline NG117.

  6. Rapid tranquillisation in mental health settings: promethazine hydrochloride (ESUOM28)

    This evidence summary has been updated and replaced by NICE guideline NG10.

  7. Chronic pain: oral ketamine (ESUOM27)

    This evidence summary has been updated and replaced by NICE guideline NG193.

  8. Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)

    This evidence summary has been updated and replaced by NICE guideline NG71.

  9. Type 1 diabetes: insulin degludec (ESNM24)

    This evidence summary has been updated and replaced by NICE guideline NG17.

  10. Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

    This evidence summary has been updated and replaced by NICE guideline NG131.

  11. Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

    This evidence summary has been updated and replaced by NICE guideline NG117.

  12. Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

    This evidence summary has been updated and replaced by NICE guideline NG201.

  13. Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

    This evidence summary has been updated and replaced by NICE guideline NG71.

  14. Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)

    This evidence summary has been updated and replaced by NICE guideline CG61.